Cargando…

Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions

ABSTRACT: Microbial production of antibodies offers the promise of cheap, fast, and efficient production of antibodies at an industrial scale. Limiting this capacity in prokaryotes is the absence of the post-translational machinery, present in dedicated antibody producing eukaryotic cell lines, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Lénon, Marine, Ke, Na, Szady, Cecily, Sakhtah, Hassan, Ren, Guoping, Manta, Bruno, Causey, Bryce, Berkmen, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595990/
https://www.ncbi.nlm.nih.gov/pubmed/32997203
http://dx.doi.org/10.1007/s00253-020-10920-5
_version_ 1783602008255627264
author Lénon, Marine
Ke, Na
Szady, Cecily
Sakhtah, Hassan
Ren, Guoping
Manta, Bruno
Causey, Bryce
Berkmen, Mehmet
author_facet Lénon, Marine
Ke, Na
Szady, Cecily
Sakhtah, Hassan
Ren, Guoping
Manta, Bruno
Causey, Bryce
Berkmen, Mehmet
author_sort Lénon, Marine
collection PubMed
description ABSTRACT: Microbial production of antibodies offers the promise of cheap, fast, and efficient production of antibodies at an industrial scale. Limiting this capacity in prokaryotes is the absence of the post-translational machinery, present in dedicated antibody producing eukaryotic cell lines, such as B cells. There has been few and limited success in producing full-length, correctly folded, and assembled IgG in the cytoplasm of prokaryotic cell lines. One such success was achieved by utilizing the genetically engineered Escherichia coli strain SHuffle with an oxidative cytoplasm. Due to the genetic disruption of reductive pathways, SHuffle cells are under constant oxidative stress, including increased levels of hydrogen peroxide (H(2)O(2)). The oxidizing capacity of H(2)O(2) was linked to improved disulfide bond formation, by expressing a fusion of two endoplasmic reticulum-resident proteins, the thiol peroxidase GPx7 and the protein disulfide isomerase, PDI. In concert, these proteins mediate disulfide transfer from H(2)O(2) to target proteins via PDI-Gpx7 fusions. The potential of this new strain was tested with Humira, a blockbuster antibody usually produced in eukaryotic cells. Expression results demonstrate that the new engineered SHuffle strain (SHuffle2) could produce Humira IgG four-fold better than the parental strain, both in shake-flask and in high-density fermentation. These preliminary studies guide the field in genetically engineering eukaryotic redox pathways in prokaryotes for the production of complex macromolecules. KEY POINTS: • A eukaryotic redox pathway was engineered into the E. coli strain SHuffle in order to improve the yield of the blockbuster antibody Humira. • The best peroxidase-PDI fusion was selected using bioinformatics and in vivo studies. • Improved yields of Humira were demonstrated at shake-flask and high-density fermenters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00253-020-10920-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7595990
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75959902020-11-10 Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions Lénon, Marine Ke, Na Szady, Cecily Sakhtah, Hassan Ren, Guoping Manta, Bruno Causey, Bryce Berkmen, Mehmet Appl Microbiol Biotechnol Applied Genetics and Molecular Biotechnology ABSTRACT: Microbial production of antibodies offers the promise of cheap, fast, and efficient production of antibodies at an industrial scale. Limiting this capacity in prokaryotes is the absence of the post-translational machinery, present in dedicated antibody producing eukaryotic cell lines, such as B cells. There has been few and limited success in producing full-length, correctly folded, and assembled IgG in the cytoplasm of prokaryotic cell lines. One such success was achieved by utilizing the genetically engineered Escherichia coli strain SHuffle with an oxidative cytoplasm. Due to the genetic disruption of reductive pathways, SHuffle cells are under constant oxidative stress, including increased levels of hydrogen peroxide (H(2)O(2)). The oxidizing capacity of H(2)O(2) was linked to improved disulfide bond formation, by expressing a fusion of two endoplasmic reticulum-resident proteins, the thiol peroxidase GPx7 and the protein disulfide isomerase, PDI. In concert, these proteins mediate disulfide transfer from H(2)O(2) to target proteins via PDI-Gpx7 fusions. The potential of this new strain was tested with Humira, a blockbuster antibody usually produced in eukaryotic cells. Expression results demonstrate that the new engineered SHuffle strain (SHuffle2) could produce Humira IgG four-fold better than the parental strain, both in shake-flask and in high-density fermentation. These preliminary studies guide the field in genetically engineering eukaryotic redox pathways in prokaryotes for the production of complex macromolecules. KEY POINTS: • A eukaryotic redox pathway was engineered into the E. coli strain SHuffle in order to improve the yield of the blockbuster antibody Humira. • The best peroxidase-PDI fusion was selected using bioinformatics and in vivo studies. • Improved yields of Humira were demonstrated at shake-flask and high-density fermenters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00253-020-10920-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-30 2020 /pmc/articles/PMC7595990/ /pubmed/32997203 http://dx.doi.org/10.1007/s00253-020-10920-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Applied Genetics and Molecular Biotechnology
Lénon, Marine
Ke, Na
Szady, Cecily
Sakhtah, Hassan
Ren, Guoping
Manta, Bruno
Causey, Bryce
Berkmen, Mehmet
Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title_full Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title_fullStr Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title_full_unstemmed Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title_short Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
title_sort improved production of humira antibody in the genetically engineered escherichia coli shuffle, by co-expression of human pdi-gpx7 fusions
topic Applied Genetics and Molecular Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595990/
https://www.ncbi.nlm.nih.gov/pubmed/32997203
http://dx.doi.org/10.1007/s00253-020-10920-5
work_keys_str_mv AT lenonmarine improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT kena improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT szadycecily improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT sakhtahhassan improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT renguoping improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT mantabruno improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT causeybryce improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions
AT berkmenmehmet improvedproductionofhumiraantibodyinthegeneticallyengineeredescherichiacolishufflebycoexpressionofhumanpdigpx7fusions